Namodenoson for advanced liver cancer with moderate cirrhosis
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial studies whether namodenoson can slow or control advanced hepatocellular carcinoma (liver cancer) in people whose cirrhosis is in a specific middle range. It may help if standard treatments have not worked or the cancer has spread and is not expected to be cured.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have advanced liver cancer (hepatocellular carcinoma) that has spread or cannot be cured with standard treatments.
- Your cirrhosis must be Child-Pugh class B7 (a staging system for liver function).
- You have had 1 or 2 prior “whole-body” cancer medicine treatments (no more than 2).
- Your recent lab tests must meet thresholds (low enough bilirubin, liver enzymes not too high, and enough blood counts and kidney function).
- You can get trial visits and blood tests as scheduled, and you agree to sign informed consent.
- You have not had certain treatments too recently (no cancer medicine in the last 4 weeks, and no local procedures/surgery/radiation in the last 4 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if memantine, a medication typically used for memory problems, can help people with advanced liver cancer and cirrhosis. It is for those who cannot have standard aggressive treatments.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This study tests a new way to treat liver cancer that can't be removed with surgery. It combines a targeted drug (donafenib) with a procedure called E-TACE, which delivers chemotherapy directly to the tumor. The goal is to see if this combination works better than standard treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.